Prevention of radiotherapy induced enteropathy by probiotics (PREP): protocol for a double-blind randomized placebo-controlled trial

Yeon Joo Kim, Jesang Yu, Sung Pyo Park, Seung Hae Lee, Young Seok Kim, Yeon Joo Kim, Jesang Yu, Sung Pyo Park, Seung Hae Lee, Young Seok Kim

Abstract

Background: Radiation induced enteropathy is a common complication of radiotherapy for pelvic tumors and adversely affects patient quality of life. Probiotics are thought to restore bowel microflora to optimal levels and reinforce intestinal barrier capacity. Although probiotics are effective in the treatment of radiation induced enteropathy, less is known about their efficacy to prevent radiation induced enteropathy.

Methods: This double-blind randomized placebo-controlled study will investigate the efficacy of probiotics to prevent radiation-induced enteropathy in patients with gynecologic or urologic cancer who received pelvic radiotherapy. The study is designed to enroll 248 eligible patients, who will be randomized 1:1 to a probiotic or placebo group. Toxicities will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Discussion: The primary aim of this study is to provide high level evidence for the ability of probiotics to prevent acute radiation induced enteropathy. The secondary aims are to determine the effects of probiotics on the incidence of chronic radiation induced enteropathy and the safety of probiotics in patients with gynecologic or urologic cancer.

Trial registration: ClinicalTrials.gov ( NCT03978949 , Registered on 7 June 2019).

Keywords: Efficacy; Enteropathy; Probiotics; Radiotherapy; Safety.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
PREP study schema
Fig. 2
Fig. 2
Intervention and assessment schedule for the PREP trial according to the recommendations for interventional trials (SPIRIT)

References

    1. Hauer-Jensen M, Denham JW, Andreyev HJN. Radiation enteropathy--pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol. 2014;11(8):470–479. doi: 10.1038/nrgastro.2014.46.
    1. Abayomi J, Kirwan J, Hackett A. The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life. Eur J Oncol Nurs. 2009;13(4):262–267. doi: 10.1016/j.ejon.2009.02.007.
    1. Hotel ACP, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention. 2001;5(1):1–10.
    1. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: a review. ISRN Nutr. 2013;2013:481651. doi: 10.5402/2013/481651.
    1. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–767. doi: 10.1016/j.clnu.2013.10.015.
    1. Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912–915. doi: 10.3748/wjg.v13.i6.912.
    1. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol. 2001;13(4):391–396. doi: 10.1097/00042737-200104000-00015.
    1. Fuccio L, Guido A, Eusebi LH, Laterza L, Grilli D, Cennamo V, Ceroni L, Barbieri E, Bazzoli F. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol. 2009;43(6):506–513. doi: 10.1097/MCG.0b013e3181a1f59c.
    1. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–S153. doi: 10.1097/MCG.0b013e3182257e98.
    1. Liu MM, Li ST, Shu Y, Zhan HQ. Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(6):e0178870. doi: 10.1371/journal.pone.0178870.
    1. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013;21(1):313–326. doi: 10.1007/s00520-012-1644-z.
    1. Oh B, Eade T, Lamoury G, Carroll S, Morgia M, Kneebone A, et al. The gut microbiome and gastrointestinal toxicities in pelvic radiation therapy: a clinical review. Cancers. 2021;13(10):2353. 10.3390/cancers13102353.
    1. Liu J, Liu C. Yue JJRO, Radiotherapy and the gut microbiome: facts and fiction. Cancers. 2021;16(1):1–15. 10.1186/s13014-020-01735-9.
    1. Dasari P, Vivekanandam S, Raghava KSA. Radiation for Gynaecological malignancies. Radiotherapy. 2017;63. 10.5772/67202.
    1. Network NCC. NCCN clinical practice guidelines in oncology, prostate cancer—version 4.2019. 2019.
    1. Kim YJ, Byun SJ, Ahn H, Kim C-S, Hong B-S, Yoo S, Lee JL, Kim YS. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis. Oncotarget. 2017;8(40):68996–69004. doi: 10.18632/oncotarget.16576.
    1. Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Stenfert Kroese MC, Nijman HW, van de Poll-Franse LV, Creutzberg CL. Five-year quality of life of endometrial cancer patients treated in the randomised post operative radiation therapy in endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012;48(11):1638–1648. doi: 10.1016/j.ejca.2011.11.014.
    1. Joo JH, Kim YJ, Kim YS, Choi EK, Kim JH, Lee S-W, Song SY, Yoon SM, Kim SS, Park JH, Jeong Y, Ahn H, Kim CS, Lee JL, Ahn SD. Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report. Radiat Oncol J. 2013;31(4):199–205. doi: 10.3857/roj.2013.31.4.199.
    1. Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W, Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol. 2018;36(24):2538–2544. doi: 10.1200/JCO.2017.77.4273.
    1. Nomoto K. Prevention of infections by probiotics. J Biosci Bioeng. 2005;100(6):583–592. doi: 10.1263/jbb.100.583.
    1. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol. 2018;233(3):2091–2103. doi: 10.1002/jcp.25911.
    1. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(3):286–299. doi: 10.1097/00054725-200405000-00018.
    1. Linn YH, Thu KK, Win NHH. Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients: a randomized double-blind placebo-controlled study. Probiotics Antimicrobial Proteins. 2019;11(2):638–647. doi: 10.1007/s12602-018-9408-9.
    1. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010;5(1):31. doi: 10.1186/1748-717X-5-31.
    1. Giralt J, Regadera JP, Verges R, Romero J, de la Fuente I, Biete A, Villoria J, Cobo JM, Guarner F. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys. 2008;71(4):1213–1219. doi: 10.1016/j.ijrobp.2007.11.009.
    1. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115(1):178–181. doi: 10.1542/peds.2004-2137.
    1. Richard V, Van Der Auwera P, Snoeck R, Daneau D, Meunier F. Nosocomial bacteremia caused byBacillus species. Eur J Clin Microbiol Infect Dis. 1988;7(6):783–785. doi: 10.1007/BF01975049.
    1. Redman M, Ward E, Phillips R. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919–1929. doi: 10.1093/annonc/mdu106.
    1. Horosheva TV, Vodyanoy V, Sorokulova I. Efficacy of Bacillus probiotics in prevention of antibiotic-associated diarrhoea: a randomized, double-blind, placebo-controlled clinical trial. JMM Case Rep. 2014;1(3). 10.1099/jmmcr.0.004036.
    1. Sorokulova IB, Pinchuk IV, Denayrolles M, Osipova IG, Huang JM, Cutting SM, Urdaci MC. The safety of two Bacillus probiotic strains for human use. Dig Dis Sci. 2008;53(4):954–963. doi: 10.1007/s10620-007-9959-1.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel